Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy

Completed · Phase 1

Conditions studied: Nonarteritic Anterior Ischemic Optic Neuropathy

In brief

The purpose of this study is to explore the safety and efficacy of ranibizumab to treat non-arteritic ischemic optic neuropathy based on clinical and anatomical findings.

Key facts

Study ID

NCT00561834

Run by

University of Colorado, Denver

People needed

2

Starts

2007-11-01

Expected to finish

2009-04-01

Last updated by the study team

2016-09-30

Who can join

Age: 21 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• provide written informed consent
• 21 years of age or older
• new onset, within 14 days, of ischemia and vision loss
• Best Corrected Visual Acuity (BCVA) 20/40 or worse

You may not qualify if…

• pregnancy or lactation
• proliferative diabetic retinopathy,
• diabetic macular edema,
• uveitis,
• history of ocular trauma,
• severe glaucoma,
• age-related macular degeneration.
• prior or concomitant treatment of oral steroids within 30 days,
• participation in any studies of investigational drugs within 30 days,
• participation in a ranibizumab clinical trial or,
• prior treatment intravitreally or intravenously of Avastin or steroids.

Where it is running

• Rocky Mountain Lions Eye Institute — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.